Year Founded
2021
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Small molecule

Actio Biosciences General Information

First participant dosed in Phase 1 trial of ABS-0871 for CMT2C

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

ABS-0871
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Actio Biosciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Actio Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Actio Biosciences's complete valuation and funding history, request access »

Actio Biosciences Investors

top healthcare investors
Investor Type: Venture Capital
Holding: Minority